Targeted protein degradation companies develop medicines that direct disease-associated proteins towards the cell’s natural disposal machinery. These technologies can remove proteins rather than simply blocking their activity, creating new approaches to previously difficult drug targets.
This category includes companies working on:
Browse 13 UK targeted protein degradation companies below.
Automated chiral chemistry platform for small molecule drug discovery
LCC Technologies is a drug discovery company providing biopharma partners with access to its platform, which combines a proprietary billion-scale virtual chiral library with…
Specialty chemical building blocks and reagents for drug discovery research
Fluorochem is a UK manufacturer and supplier of specialty chemicals, reagents and biochemical building blocks, with a catalogue spanning several hundred thousand products used…
AI platform engineering molecular glue drugs for undruggable targets
Ternary Therapeutics is a preclinical-stage biotechnology company developing an AI-driven platform for the rational design of molecular glue therapeutics. Molecular glues are…
Chemistry-led CRO and CDMO for pharmaceutical and diagnostics R&D
High Force Research is an independent chemistry CRO and CDMO providing synthetic chemistry, process development, and GMP manufacturing services to the pharmaceutical, biotech, and…
Integrated contract drug discovery from Cambridge and India
o2h is a contract research organisation operating an integrated drug discovery platform from Cambridge, UK, and Ahmedabad, India. Core services span medicinal chemistry, biology,…
Phenotypic screening platform for targeted protein degradation drug discovery
PhoreMost is a drug discovery company developing a phenotypic screening platform to identify and prosecute previously undruggable disease targets. The platform systematically…
Small molecule protein degraders targeting oncology and CNS disease
Kesmalea Therapeutics is a biotechnology company developing oral small molecule therapeutics that modulate protein homeostasis through targeted protein degradation and…
Precision oncology drug discovery via targeted protein degradation
Dark Blue Therapeutics is a precision oncology biotech focused on discovering and developing first-in-class small molecule drugs. The company applies targeted protein degradation…
Targeted protein degradation platform for neurodegenerative disease
TRIMTECH Therapeutics is a biotechnology company developing small-molecule degraders that selectively remove disease-causing protein aggregates while preserving the functional,…
Tunable covalent chemistry platform for neurodegenerative disease
Dunad Therapeutics is a drug discovery biotech developing small molecule therapies for neurodegenerative diseases including ALS, frontotemporal dementia, and Parkinson's disease.…
Next-generation targeted protein degradation therapeutics
Amphista Therapeutics is a Cambridge-based biopharmaceutical company developing next-generation targeted protein degradation medicines. Its proprietary platform generates…
E3 ligase inhibitors stabilising tumour suppressor proteins
Outrun Therapeutics is a preclinical drug discovery company developing small molecule inhibitors of E3 ligase enzymes to stabilise tumour suppressor and other disease-relevant…